Patents by Inventor Algis Anilionis
Algis Anilionis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5961983Abstract: This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live vaccine bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.Type: GrantFiled: May 24, 1995Date of Patent: October 5, 1999Assignee: Praxis Biologics, Inc.Inventors: Robert N. Brey, James P. Fulginiti, Algis Anilionis
-
Patent number: 5919663Abstract: This invention pertains to a complementation system for the selection and maintenance of expressed genes in bacterial hosts. The invention provides stable vectors which can be selected and maintained by complementation of chromosomal deletion mutations of purA (adenylosuccinate synthetase), obviating the use of antibiotic resistance genes. This system is useful in production organisms during fermentation and in live vaccine bacteria, such as attenuated Salmonella typhi. This system allows for selection of chromosomal integrants and for selection and stable plasmid maintenance in the vaccinated host without application of external selection pressure.Type: GrantFiled: January 30, 1995Date of Patent: July 6, 1999Assignee: American Cyanamid CompanyInventors: Robert N. Brey, James P. Fulginiti, Algis Anilionis
-
Patent number: 5616473Abstract: The gene encoding the ligninase rLDM.TM. 6 has been cloned and expressed. The ligninases produced via the processes disclosed herein are useful to degrade or modify lignin in pulp operations.Type: GrantFiled: August 8, 1994Date of Patent: April 1, 1997Assignee: Clariant Finance (BVI) LimitedInventors: Roberta L. Farrell, Paul Gelep, Algis Anilionis, Kashayar Javaherian, Theodore E. Maione, James Rusche, Bruce A. Sadownick, Jennifer A. Jackson
-
Patent number: 5196338Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.Type: GrantFiled: February 15, 1990Date of Patent: March 23, 1993Assignee: Praxis Biologics, Inc.Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
-
Patent number: 5151350Abstract: The gene coding for a protein A-like material has been successfully cloned and expressed for the first time. The cloning of this gene with its nucleotide sequence characterization, also disclosed, enables those skilled in the art to obtain quantities of a protein A-like material nucleotide sequence for cloning in various host-vector systems. Protein A is well known as a valuable component of a variety of diagnostic test systems. The protein A-like material of the subject invention, and subfragments thereof, have the protein A properties of binding to IgG at the Fc region and activation of polyclonal antibody synthesis. Thus, these entities are useful in the same manner as protein A.Type: GrantFiled: October 27, 1982Date of Patent: September 29, 1992Assignee: Repligen CorporationInventors: Donald A. Colbert, Algis Anilionis
-
Patent number: 5110905Abstract: The subject invention is directed to a novel Bacillus thuringiensis kurstaki .delta.-endotoxin prepared by use of a novel hybrid gene. This gene is cloned into a novel plasmid which is transformed into a prokaryotic host. The .delta.-endotoxin of the subject invention is active against Lepidoptera larvae.Type: GrantFiled: July 27, 1990Date of Patent: May 5, 1992Assignee: Repligen CorporationInventors: Daniel P. Witt, Donald A. Colbert, Algis Anilionis
-
Patent number: 5098997Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides, proteins, and fusion proteins in appropriate host cells. The peptides, proteins, fusion proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections.Type: GrantFiled: September 1, 1988Date of Patent: March 24, 1992Assignee: Praxis Biologics, Inc.Inventors: Algis Anilionis, Robert C. Seid, Jr., Robert A. Deich, Gary W. Zlotnick, Bruce A. Green
-
Patent number: 4952682Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promoter DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.Type: GrantFiled: September 30, 1988Date of Patent: August 28, 1990Assignee: Repligen CorporationInventors: Algis Anilionis, John L. Palmer
-
Patent number: 4888280Abstract: Hybrid useful proteins are prepared by a novel biological system comprising a prokaryotic host transformed with novel hybrid plasmids' .beta.-glucuronidase (BG) gene DNZ and the desired protein gene DNA. Specifically exemplified are plasmids which comprise BG gene DNA and protein A DNA. E. coli K-12 derivative hosts transformed with plasmid pBG3-2.DELTA.n express >60% of the desired fusion protein having protein A-like biological activity. Other useful proteins can be expressed via the elegant highly efficient expression system of the subject invention.Type: GrantFiled: August 25, 1986Date of Patent: December 19, 1989Assignee: Repligen CorporationInventors: John L. Palmer, Algis Anilionis
-
Patent number: 4721671Abstract: A novel highly effective prokaryotic expression system is exemplified specifically by being used to produce the useful enzyme .beta.-glucuronidase (BG). This system uses a hybrid plasmid comprising BG gene promotor DNA. The level of expression of BG by an E. coli K-12 derivative host is in the 50% of total cellular protein range. The invention expression system also can be used to express other useful proteins, as disclosed herein.Type: GrantFiled: December 26, 1984Date of Patent: January 26, 1988Assignee: Repligen CorporationInventors: Algis Anilionis, John L. Palmer
-
Patent number: 4691009Abstract: Hybrid useful proteins are prepared by a novel biological system comprising a prokaryotic host transformed with novel hybrid plasmids' .beta.-glucuronidase (BG) gene DNA and the desired protein gene DNA. Specifically exemplified are plasmids which comprise BG gene DNA and protein A DNA. E. coli K-12 derivative hosts transformed with plasmid pBG3-2.DELTA.N express >60% of the desired fusion protein having protein A-like biological activity. Other useful proteins can be expressed via the elegant highly efficient expression system of the subject invention.Type: GrantFiled: December 26, 1984Date of Patent: September 1, 1987Assignee: Repligen CorporationInventors: John L. Palmer, Algis Anilionis